XML 79 R60.htm IDEA: XBRL DOCUMENT v3.25.1
Moderna Collaboration and License Agreement - Narrative (Details)
$ in Thousands
1 Months Ended 12 Months Ended
Jan. 31, 2025
USD ($)
Sep. 30, 2024
target
Jun. 30, 2024
USD ($)
Jan. 31, 2022
USD ($)
target
product
Dec. 31, 2024
USD ($)
target
obligation
Dec. 31, 2023
USD ($)
Feb. 28, 2025
target
Dec. 31, 2022
USD ($)
Moderna Collaboration and License Agreement                
Collaboration revenues         $ 19,600 $ 14,900    
Deferred revenue liability         44,979 46,413   $ 47,459
Collaboration revenues         19,632 $ 14,919    
Option Right Collaboration Revenues                
Moderna Collaboration and License Agreement                
Collaboration revenues         3,800      
Milestones                
Moderna Collaboration and License Agreement                
Collaboration revenues         2,000      
Moderna                
Moderna Collaboration and License Agreement                
Collaboration receivable         $ 2,900      
Moderna | Subsequent Event                
Moderna Collaboration and License Agreement                
Proceeds from collection of collaboration receivable $ 2,900              
Collaboration and License Agreement                
Moderna Collaboration and License Agreement                
Number of potential research target designations | target         12      
Collaboration and License Agreement | Research and Development Services                
Moderna Collaboration and License Agreement                
Variable consideration         $ 73,900      
Term of contract (in years)         5 years      
Noncurrent portion of deferred revenue         $ 41,300      
Collaboration and License Agreement | Moderna                
Moderna Collaboration and License Agreement                
Maximum of research targets | target       12        
Number of nominated autoimmune target | target   2            
Collaboration and License Agreement | Moderna | Subsequent Event                
Moderna Collaboration and License Agreement                
Number of oncology research targets | target             12  
Collaboration and License Agreement | Moderna | Research and Development Services                
Moderna Collaboration and License Agreement                
Upfront non-refundable payment received       $ 45,000 $ 45,000      
Number of potential products to develop and commercialize | product       12        
Minimum commitment to reimburse research and development costs       $ 10,000        
Period of reimbursement of research and development costs (in years)       3 years        
Number of performance obligations | obligation         2      
Collaboration and License Agreement | Moderna | Minimum | Research and Development Services                
Moderna Collaboration and License Agreement                
Amount receivable per product       $ 247,000        
Collaboration and License Agreement | Moderna | Maximum | Research and Development Services                
Moderna Collaboration and License Agreement                
Amount receivable per product       $ 253,000        
Moderna License Agreement | Research and Development Services                
Moderna Collaboration and License Agreement                
Collaboration revenues         $ 38,700      
Moderna License Agreement | Moderna                
Moderna Collaboration and License Agreement                
Milestone payment     $ 2,000          
Collaboration revenues     $ 2,000          
Deferred revenue liability         45,000      
Decrease in contract with customer, liability         $ 3,800